# Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia

> **NCT02130765** · NA · TERMINATED · sponsor: **Abbott Medical Devices** · enrollment: 64 (actual)

## Conditions studied

- Monomorphic Ventricular Tachycardia

## Interventions

- **DEVICE:** Cardiac catheter ablation with ICD/CRT-D

## Key facts

- **NCT ID:** NCT02130765
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2016-07-25
- **Final completion:** 2016-07-25
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Terminated due to low enrollment rate.
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02130765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02130765, "Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02130765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*